Brancaccio R*, Gigante L, Delfino G, Florio G and Patella V
Department of Internal Medicine ASL Salerno, ???¢????????Santa Maria della Speranza???¢??????? Hospital, Salerno, Italy Postgraduate Program in Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy
Posters & Accepted Abstracts: Health Sci J
Background and aims: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is characterized by an heavy symptomatic burden and low quality of life (QoL). CRSwNP shows a type 2 inflammatory background, including high levels of IL-4 and IL-13. Sharing the same physiopathology, asthma is a common comorbidity of CRSwNP. When associated, asthma and CRSwNP have both a worse prognosis [1]. Dupilumab is a monoclonal antibody inhibiting IL-4 and IL-13 [2]. The aim of this study is evaluating anti-IL4Rα treatment in CRSwNP with asthma comorbidity in real life. Materials/Patients: 10 patients affected by CRSwNP and asthma (≥18 years, mean 36,6±14,7, 7M and 3F) were recruited. Methods: Every patient underwent a treatment with dupilumab according to data sheet. At the beginning of treatment (T0) and 16 weeks after (T1) TENPS, SNOT-22, FEV1 e ACT were evaluated. Results: SNOT-22 [T0=42,0 ± 23,9; T1=17 ± 6,2; -25 (-59,5%) p<0,001]; TENPS [T0=4,5 ± 2,1; T1= 2,0 ± 1,7; -2,5 (-45,5%) p<0,001]; ACT [T0=18,0 ± 5,6; T1=23,0 ± 2,6; +5,0 (+27,0%) p<0,001]; FEV1 [T0=86% ± 21; T1=108% ± 28; +22,0% p<0,001] (Figure 1). Discussion: Our study shows anti-IL4Rα treatment efficacy, both on clinical and QoL parameters. If confirmed in a larger cohort, these data could open a new scenario in patients affected by CRSwNP and asthma resistant to conventional treatment. References 1. Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic Rhinosinusitis with Nasal Polyps and Asthma. J allergy Clin Immunol Pract 9: 1133–1141. 2. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, et al. (2017) Long-term management of moderateto- severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389: 2287-2303.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 